Ken Griffin’s Cellectar Biosciences CLRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11,442
| Closed | -$108K | – | 5958 |
|
|
2025
Q1 | $108K | Buy |
+11,442
| New | +$108K | ﹤0.01% | 5125 |
|
|
2024
Q4 | – | Sell |
-10
| Closed | -$648 | – | 6076 |
|
|
2024
Q3 | $648 | Sell |
10
-1,664
| -99% | -$108K | ﹤0.01% | 5645 |
|
|
2024
Q2 | $126K | Sell |
1,674
-2,249
| -57% | -$169K | ﹤0.01% | 4863 |
|
|
2024
Q1 | $468K | Buy |
3,923
+1,623
| +71% | +$194K | ﹤0.01% | 3985 |
|
|
2023
Q4 | $191K | Buy |
+2,300
| New | +$191K | ﹤0.01% | 4628 |
|
|
2023
Q3 | – | Sell |
-1,026
| Closed | -$60K | – | 5934 |
|
|
2023
Q2 | $60K | Buy |
+1,026
| New | +$60K | ﹤0.01% | 4933 |
|
|
2023
Q1 | – | Sell |
-622
| Closed | -$31.9K | – | 5989 |
|
|
2022
Q4 | $31.9K | Buy |
+622
| New | +$31.9K | ﹤0.01% | 5418 |
|
|
2022
Q3 | – | Sell |
-230
| Closed | -$28K | – | 5966 |
|
|
2022
Q2 | $28K | Buy |
+230
| New | +$28K | ﹤0.01% | 5648 |
|
|
2022
Q1 | – | Sell |
-549
| Closed | -$109K | – | 6427 |
|
|
2021
Q4 | $109K | Buy |
+549
| New | +$109K | ﹤0.01% | 5855 |
|
|
2021
Q1 | – | Sell |
-114
| Closed | -$71K | – | 6309 |
|
|
2020
Q4 | $71K | Buy |
+114
| New | +$71K | ﹤0.01% | 4778 |
|
|
2020
Q2 | – | Sell |
-41
| Closed | -$15K | – | 4698 |
|
|
2020
Q1 | $15K | Buy |
+41
| New | +$15K | ﹤0.01% | 4695 |
|
|
2019
Q2 | – | Sell |
-59
| Closed | -$42K | – | 4681 |
|
|
2019
Q1 | $42K | Buy |
59
+10
| +20% | +$7.12K | ﹤0.01% | 4273 |
|
|
2018
Q4 | $23K | Buy |
+49
| New | +$23K | ﹤0.01% | 4229 |
|
|
2018
Q3 | – | Sell |
-19
| Closed | -$35K | – | 4331 |
|
|
2018
Q2 | $35K | Buy |
+19
| New | +$35K | ﹤0.01% | 3956 |
|
|
2018
Q1 | – | Sell |
-5
| Closed | -$19K | – | 4014 |
|
|
2017
Q4 | $19K | Buy |
+5
| New | +$19K | ﹤0.01% | 3772 |
|
|
2017
Q2 | – | Sell |
-6
| Closed | -$43K | – | 3705 |
|
|
2017
Q1 | $43K | Buy |
+6
| New | +$43K | ﹤0.01% | 3423 |
|